Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | BRD1 | O95696 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4690041 | 1.00 | HTR6 (0.42) | HTR6KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL4690178 | 0.92 | DRD2 (0.44) | HTR6KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL4690184 | 0.92 | DRD2 (0.44) | HTR6KMT2ADRD2DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL27635996 | 0.91 | DRD2 (0.43) | HTR6KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL4689876 | 0.89 | ALDH1A1 (0.50) | KMT2AKCNH2ALDH1A1MAPT | |
| SCHEMBL4689873 | 0.89 | ALDH1A1 (0.50) | KMT2AKCNH2ALDH1A1MAPT | |
| SCHEMBL15061389 | 0.89 | KMT2A (0.53) | HTR6KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL4688586 | 0.89 | KMT2A (0.53) | HTR6KMT2ADRD2DRD3KCNH2 | |
| Hydrochloric Acid SCHEMBL4692989 | 0.88 | KMT2A (0.52) | HTR6KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL4689843 | 0.87 | DRD2 (0.47) | HTR6KMT2ADRD2DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | claimed |
| US-8476275-B2 | N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-1613596-B1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2008-03-12 | — | — | EP | disclosed |
| US-7320979-B2 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | ABBOTT GMBH & CO. KG (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | ABBOTT GMBH & CO. KG. | 2006-07-20 | — | — | US | disclosed |
| EP-1613596-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004089905-A1 | N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294817-A1 | N-[PIPERAZINYL HETARYL]ARYLSUFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR | DRD2, DRD3, TACR1 | HTR6 151/4885KMT2A 4228/4885DRD2 1/4885 |
| US-20070054918-A1 | N-[(piperazinyl)hetary]arylsulfonamide compounds with affinity for the dopamine d3 receptor | PTGDR, TACR1, TACR2 | HTR6 105/4885KMT2A 4198/4885DRD2 5/4885 |
| US-20060160809-A1 | N-[(piperazinyl)hetaryl]arylsulfonamide compounds | CBR3, CNR2, CNR1 | HTR6 171/4885KMT2A 4399/4885DRD2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.